Lincoln University researchers have received United States Food and Drug Administration approval for in-human clinical trials of their gene therapy for the treatment of CLN5 Batten disease, a fatal neurodegenerative disease affecting children. The CLN5 form of Batten disease appears early in a child’s life and causes brain degeneration manifesting in devastating symptoms including vision...